The future outlook for Race Oncology (ASX: RAC) depends heavily on the clinical and commercial success of its ongoing Phase 1 and Phase 3 trial pipelines for its proprietary bisantrene drug formulations. While positive data releases regarding drug efficacy, strategic pharmaceutical partnerships, and expanding clinical trials provide potential catalysts for upward valuation, investors must also account for typical biotechnology risks such as cash burn rates, regulatory hurdles, and clinical trial volatility.